

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

2021 FIRST QUARTERLY REPORT

This announcement is made pursuant to Rules 13.09 (2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The following is the first quarterly report of Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) for the financial year 2021. This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the accompanying financial statements were prepared in accordance with the China Accounting Standards for Business Enterprises and have not been audited.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, April 28, 2021

As at the date of this announcement, the executive Directors of the Company are Dr. Ye Xiaoping, Ms. Cao Xiaochun and Ms. Yin Zhuan; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.

HANGZHOU TIGERMED CONSULTING CO., LTD.

2021 First Quarterly Report

April 2021

SECTION 1 IMPORTANT

The Board of Directors, Board of Supervisors, Directors, Supervisors and senior management of the Company warrant that the contents of the quarterly report are true, accurate and complete and there is no false representation, misleading statement or material omission, and take legal responsibilities jointly and severally.

All Directors have attended the Board meeting approving this quarterly report.

Cao Xiaochun, head of the Company, Gao Jun, person-in-charge of accounting affairs and Yu Guoyun, head of accounting department (accounting supervisor) warrant the truthfulness, accuracy and completeness of the financial statements contained in this quarterly report.

SECTION 2 BASIC PARTICULARS OF THE COMPANY

I. MAJOR ACCOUNTING DATA AND FINANCIAL INDICATORS

Whether retrospective adjustments or restatements would be made by the Company to the accounting data for prior years

Yes No

	Reporting Period	Prior Period	Change
Revenue (RMB)	901,947,880.46	650,105,123.66	38.74%
Net profit attributable to owners of the parent (RMB)	455,480,291.91	254,960,034.72	78.65%
Net profit attributable to owners of the parent after deducting extraordinary gain or loss (RMB)	228,909,261.61	115,395,514.61	98.37%
Net cashflow from operating activities (RMB)	238,339,757.83	88,916,057.98	168.05%
Basic earnings per share (RMB/share)	0.52	0.34	52.94%
Diluted earnings per share (RMB/share)	0.52	0.34	52.94%
Weighted average return on net assets	2.54%	5.83%	-3.29%

	End of the Reporting Period	End of prior year	Change
Total assets (RMB)	20,281,478,168.44	19,506,057,719.48	3.98%
Net assets attributable to owners of the parent (RMB)	16,423,146,659.90	16,118,568,008.27	1.89%

Items and amounts of extraordinary gain or loss

✓ Applicable Not applicable

Unit: RMB

Item	Amounts from the beginning of the year to the end of the Reporting Period	Remarks
Gain or loss from disposal of non-current assets (including those already written off in the provision for impairment of assets)	-11,029.98	Mainly due to the disposal of long-term assets including the long-term equity investments and fixed assets by the Company during the Reporting Period.
Government grants (except for government grants which are closely related to the ordinary business of the Company and entitled in standard amounts or quantities in conformity with the uniform standards of the State) included in the profit or loss for the period	2,215,078.62	Mainly due to the government grants received by the Company during the Reporting Period.
Gain or loss from investments on trust or asset management	519,251.53	Mainly due to the income from wealth management products of the Company during the Reporting Period.

Item	Amounts from the beginning of the year to the end of the Reporting Period	Remarks
Profit or loss arising from changes in fair value of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities and derivative financial liabilities and investment gains received from disposal of held-for-trading financial assets, derivative financial assets, held-for-trading financial liabilities, derivative financial liabilities and other debt investments (except for those related to effective hedging businesses under ordinary business scope of the Company)	469,030,748.25	Mainly due to the dividend income from other non-current financial assets and the investment income from disposal of other non-current financial assets, gains from changes in fair value of other non-current assets during the Reporting Period.
Other non-operating income and expenses apart from the above items	49,824.27	
Less: Effect of income tax	-7,642,950.90	
Effect of minority interests (after tax)	252,875,793.29	
Total	226,571,030.30	–

For items of extraordinary gain or loss of defined in the *Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss*, and items of extraordinary gain or loss illustrated in the *Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss* defined as items of extraordinary gain or loss, the Company shall provide the reasons

Applicable Not applicable

During the Reporting Period, there was no item of extraordinary gain or loss defined and illustrated in the *Notice on Explanation of Information Disclosure of Companies Publicly Issuing Securities No.1 – Extraordinary Gain or Loss* defined as item of extraordinary gain or loss.

II. TOTAL NUMBER OF SHAREHOLDERS AND THE SHAREHOLDING OF TOP 10 SHAREHOLDERS AT THE END OF THE REPORTING PERIOD

1. Number of ordinary shareholders and preferred shareholders whose voting rights have been reinstated, and shareholdings of top 10 shareholders

Unit : share

Total number of ordinary shareholders as at the end of the reporting period	50,255	Total number of preferred shareholders whose voting rights have been reinstated as at the end of the reporting period (if any)	0
---	--------	--	---

Shareholding of top 10 shareholders

Name of Shareholder	Nature of Shareholder	Shareholding percentage	Number of shares held	Number of shares held subject to selling restrictions	Situation of pledged or frozen shares	
					Share status	Quantity
Ye Xiaoping	Domestic natural person	20.31%	177,239,541	132,929,656		
HKSCC NOMINEES LIMITED	Overseas legal person	14.11%	123,119,390	0		
Hong Kong Securities Clearing Company Limited	Overseas legal person	12.51%	109,168,453	0		
Cao Xiaochun	Domestic natural person	6.55%	57,161,774	42,871,330	Pledged	750,000
TEMASEK FULLERTON ALPHA PTE LTD	Overseas legal person	2.13%	18,617,328	0		
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	Others	1.82%	15,901,415	0		
Central Huijin Asset Management Co., Ltd.	State-owned legal person	1.71%	14,941,050	0		
Shi Xiaoli	Domestic natural person	1.35%	11,798,148	0	Pledged	3,600,000
Zhuan Yin	Overseas natural person	1.18%	10,296,000	7,722,000		
China Construction Bank Co., Ltd. -Yinhua rich-themed Hybrid Securities Investment Fund	Others	1.05%	9,199,905	0		

Shareholding of the top ten Shareholders not subject to selling restrictions

Name of Shareholder	Number of shares held not subject to selling restrictions	Type of shares	
		Type	Quantity
HKSCC NOMINEES LIMITED	123,119,390	Overseas listed foreign shares	123,119,390
Hong Kong Securities Clearing Company Limited	109,168,453	RMB – denominated ordinary shares	109,168,453
Ye Xiaoping	44,309,885	RMB – denominated ordinary shares	44,309,885
TEMASEK FULLERTON ALPHA PTE LTD	18,617,328	RMB – denominated ordinary shares	18,617,328
Industrial and Commercial Bank of China Limited – China-Europe Medical and Health Hybrid Securities Investment Fund	15,901,415	RMB – denominated ordinary shares	15,901,415
Central Huijin Asset Management Co., Ltd.	14,941,050	RMB – denominated ordinary shares	14,941,050
Cao Xiaochun	14,290,444	RMB – denominated ordinary shares	14,290,444
Shi Xiaoli	11,798,148	RMB – denominated ordinary shares	11,798,148
China Construction Bank Co., Ltd. -Yinhua rich-themed Hybrid Securities Investment Fund	9,199,905	RMB – denominated ordinary shares	9,199,905
Aberdeen Standard Investments (Asia) Limited – Aberdeen Standard – China A Share Equity Fund	8,140,849	RMB – denominated ordinary shares	8,140,849
Explanation of the Shareholders above who are connected or acting in concert	Ye Xiaoping and Cao Xiaochun signed the Acting-in-Concert Agreement, pursuant to which the two are persons acting in concert and the de facto controllers of the Company.		
Description of top 10 Shareholders participating in the margin trading business (if any)	Nil		

Whether the top 10 ordinary Shareholders or top ten ordinary Shareholders of the Company who are not subject to selling restrictions carried out any agreed buy-back transactions during the Reporting Period

Yes No

No agreed buy-back transaction was carried out by the top 10 ordinary Shareholders or top 10 ordinary Shareholders of the Company who are not subject to selling restrictions during the Reporting Period.

2. Total number of preferred Shareholders of the Company and the shareholding of top 10 preferred Shareholders

Applicable Not applicable

3. Changes in restricted shares

Applicable Not applicable

Unit : Share

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares released during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
Ye Xiaoping	132,929,656	0	0	132,929,656	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Cao Xiaochun	48,121,330	5,250,000	0	42,871,330	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Zhuan Yin	7,998,300	276,300	0	7,722,000	Lock-up for senior management	25% of the shares subject to lock-up for senior management to be unlocked annually
Wen Chen	1,821,540	1,821,540	0	0	Lock-up for senior management	Shares held by senior management shall be released 100% after six months upon expiry of his term of office

Name of shareholder	Number of restricted shares at the beginning of the period	Number of restricted shares released during the period	Number of restricted shares increased during the period	Number of restricted shares at the end of the period	Reasons for the restriction	Proposed date of unlocking the restricted shares
397 Incentive participants of 2019 restricted shares, including Yu Ling	3,737,094	0	0	3,737,094	Restricted shares for incentive scheme	30% of batch 1 of 2019 restricted shares have been unlocked on June 21, 2020, and the remaining 2019 restricted shares shall be unlocked as to 30% on June 21, 2021 and as to 40% on June 21, 2022
53 Incentive participants of reserved portion of 2019 restricted shares, including Jin Chengzhe	759,674	0	0	759,674	Restricted shares for incentive scheme	The reserved portion of 2019 restricted shares will be unlocked 50% on May 13, 2021 and unlocked 50% on May 13, 2022
Total	195,367,594	7,347,840	0	188,019,754	–	–

SECTION 3 IMPORTANT NOTICE

I. MATERIAL CHANGES IN KEY FINANCIAL DATA AND FINANCIAL INDICATORS DURING THE REPORTING PERIOD AND THE REASONS THEREOF

✓ Applicable Not applicable

1. Explanation of anomalies and reasons for balance sheet items

Item	Closing balance (RMB)	Opening balance (RMB)	Change	Reason(s) for the change
Financial assets held for trading	146,600,000.00	26,000,000.00	463.85%	Mainly due to the increase of wealth management products purchasing.
Other current assets	38,447,698.46	28,873,044.92	33.16%	Mainly due to the increase of wealth management products purchasing.
Construction in progress	101,204,012.52	54,839,279.79	84.55%	Mainly due to the construction of new laboratories and the increase of laboratory equipment to be installed during the Reporting Period.
Other non-current assets	44,387,117.06	110,483,924.07	-59.82%	Mainly due to the decrease of prepayment of the Company's minority shareholders' equity transfer during the Reporting Period.
Employee benefits payable	69,894,506.02	140,395,765.30	-50.22%	Mainly due to the payment of the Company's employee remuneration accrued at the end of the last year during the Reporting Period.
Non-current liabilities due within one year	269,764,696.83	105,920,524.37	154.69%	Mainly due to the increase in the fair value of the subsidiary's contingent consideration during the Reporting Period.
Long-term payables	22,282,565.53	97,493,781.83	-77.14%	Mainly due to the reclassification of the fair value of the subsidiary's contingent consideration to non-current liabilities due within one year during the Reporting Period.

2. Explanation of anomalies and reasons for income statement items

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for the change
Operating income	901,947,880.46	650,105,123.66	38.74%	Mainly due to the impact of the COVID-19 epidemic in the corresponding period and the Company's sales revenue growth in the Reporting period.
Operating cost	478,741,538.49	349,487,695.09	36.98%	Mainly due to the increase in the Company's operating income during the Reporting Period and the simultaneous increase in operating costs.
Business tax and surcharge	3,854,298.60	2,248,849.29	71.39%	Mainly due to the increase in the Company's operating income during the Reporting Period and the simultaneous increase in business tax and surcharge.
Selling expenses	31,636,114.04	22,956,268.92	37.81%	Mainly due to the increase in the Company's expenses for business team personnel and market expansion during the Reporting Period.
General and administrative expense	114,168,850.78	80,270,262.77	42.23%	Mainly due to the increase in the Company's management personnel and equity incentive expenses, and the depreciation and amortization during the Reporting Period.
Finance costs	-62,266,448.12	2,631,211.81	-2,466.46%	Mainly due to the increase in the Company's bank deposit interest income in the Reporting period.

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for the change
Investment income	32,367,209.75	76,632,752.61	-57.76%	Mainly due to the investment income generated by the fact that the investment cost of the Company's acquisition of subsidiaries in the corresponding period was less than the fair value of the investee's identifiable net assets when the investment was acquired.
Gain from fair value changes	438,176,790.03	57,707,345.36	659.31%	Mainly due to the gain on fair value changes arising from the other non-current financial assets of the Company during the Reporting Period.
Credit impairment loss	-210,159.45	-4,159,621.69	-94.95%	
Asset impairment loss	-5,485,486.02	-	NA	
Gain on disposal of assets	-5,029.98	-14,582.95	-65.51%	
Non-operating income	917,616.80	1,764,347.24	-47.99%	Mainly due to the increase in the government grants received by the Company during the corresponding period due to the outbreak of COVID-19.
Non-operating expenses	50,955.93	2,950,955.38	-98.27%	Mainly due to the increase in external donation made by the Company during the corresponding period due to the outbreak of COVID-19.
Income tax expenses	34,609,998.43	25,925,635.58	33.50%	Mainly due to the growth of the profit of the Company during the Reporting Period.

3. Explanation of anomalies and reasons for cash flow statement items

Item	Amount from the beginning of the year to the end of the Reporting Period (RMB)	Amount in the same period of prior year (RMB)	Change	Reason(s) for the change
Net cash flows from operating activities	238,339,757.83	88,916,057.98	168.05%	Mainly due to the Company's sales revenue growth and the satisfactory collection of receivables during the Reporting Period.
Net cash flows from investing activities	-746,676,378.63	-305,798,209.92	144.17%	Mainly due to the increase in minority investments in biotech companies, medical device and diagnostic research companies in order to promote the development of the bio-pharmaceutical R&D ecosystem during the Reporting Period
Net cash flows from financing activities	82,961,173.11	217,272,320.24	-61.82%	Mainly due to the increase in the Company's borrowings during the corresponding period and the Company not incurring any borrowings during the Reporting Period.

II. BUSINESS REVIEW AND OUTLOOK

Factors leading to change in business revenue during the Reporting Period

Operating income during the Reporting Period was RMB901.9479 million representing an increase of 38.74% over the corresponding period in the last year; net profit was RMB722.5540 million representing an increase of 178.62% over the corresponding period in the last year; the net profit attributable to owners of the parent was RMB455.4803 million representing an increase of 78.65% over the corresponding period in the last year; the net profit attributable to owners of the parent after deducting extraordinary gain or loss was RMB228.9093 million representing an increase of 98.37% over the corresponding period in the last year.

Major executed orders and progress

Applicable Not applicable

Scattered orders

Applicable Not applicable

Significant change in or adjustment of product or service during the reporting period

Applicable Not applicable

Progress and impact of important research and development projects

Applicable Not applicable

Impact of major changes in the Company's intangible assets, core competitiveness, core technical team or key technical personnel (non-directors, supervisors, senior management personnel) during the reporting period, and the countermeasures

Applicable Not applicable

Change in top 5 suppliers during the reporting period and its impact

Applicable Not applicable

Change in top 5 clients during the reporting period and its impact

Applicable Not applicable

Implementation of annual operating plan during the reporting period

Applicable Not applicable

Important risk factors that may adversely affect the Company's future operation, major difficulties in operations, and proposed countermeasures

Applicable Not applicable

III. EXPLANATION OF THE PROGRESS OF SIGNIFICANT EVENTS, THEIR IMPACTS AND THE ANALYSIS OF THE SOLUTIONS

Applicable Not applicable

1. On January 8, 2021, the Company convened the first extraordinary general meeting of shareholders in 2021 to consider and approve the "Resolution on 2020 A Share Employee Share Ownership Plan of Hangzhou Tigermed Consulting Co., Ltd. (Draft) and its summary" and relevant resolutions, pursuant to which, the Company was approved to implement the 2020 A Share Employee Share Ownership Plan.

On January 14, 2021, the Company convened the tenth meeting of the fourth session of the Board to consider and approve the "Resolution on the Non-trading Transfer of Shares from the Special Account for Share Repurchase to the Special Account for 2020 A Share Employee Share Ownership Plan", pursuant to which, the Company was approved to transfer 286,372 shares at RMB44.25 per share, the average transaction price of the repurchased shares, from the special account for share repurchase to the special account for "Hangzhou Tigermed Consulting Co., Ltd. – Phase I Employee Stock Ownership Plan" in a non-trading manner.

On February 1, 2021, non-trading transfer of shares for the 2020 A Share Employee Share Ownership Plan was completed. A total of 286,372 shares, accounting for 0.0328% of the Company's total share capital, has been transferred from the special account for share repurchase to "Hangzhou Tigermed Consulting Co., Ltd. – Phase I Employee Stock Ownership Plan" in a non-trading manner on February 1, 2021 at a price of RMB44.25 per share. This part of shares will be locked in accordance with related regulations, and the lock-up period will be 12 months from the date of announcement of completed transfer (i.e. February 1, 2021).

2. On March 9, 2021, the company convened the eleventh meeting of the fourth session of the board of directors and approve the "the adoption of the Subsidiary Share Option Scheme, agreeing that the Korean holding subsidiary DreamCIS INC. (hereinafter referred to as "**DreamCIS**") plans to adopt the Share Option Scheme. Under the plan, assuming that there is no change in the number of shares issued by DreamCIS between the date of the board of directors and the date of the second extraordinary general meeting in 2021, the number of DreamCIS shares covered by the plan will not exceed 559,597. The shares of DreamCIS covered by the share option plan shall not exceed 10 per cent of the total number of shares issued by DreamCIS on the date on which the share option plan of the company is approved by the general meeting of the company. On March 26, 2021, the company held the second interim general meeting of shareholders in 2021 and approve the DreamCIS Share Option Scheme.

Overview of significant events	Date of disclosure	Search index on the website disclosing the interim reports
Announcement on the completion of non-transaction transfer of 2020 A Share Employee Share Ownership Plan	February 1, 2021	http://www.cninfo.com.cn/
DreamCIS Share Option Scheme	March 10, 2021	http://www.cninfo.com.cn/

Progress in implementation of share repurchase

Applicable Not applicable

1. The Company convened the fourteenth meeting of the third session of the Board on November 12, 2018 and the 2018 fourth extraordinary general meeting on November 29, 2018 in order to consider and approve the Resolution regarding the Proposal to Repurchase Shares of the Company (《關於回購公司股份預案的議案》), the Resolution regarding the Authorization to the Board of Directors to Deal with All Matters in Relation to the Share Repurchase to be Proposed at the General Meetings (《關於提請股東大會授權董事會全權辦理本次回購股份相關事宜的議案》) and other related resolutions regarding the repurchase. The Company intended to use its own funds to repurchase part of the Company's public shares by centralized competitive bidding or other means permitted by laws and regulations as the source of shares for the subsequent implementation of the Company's 2018 Employee Stock Ownership Scheme. The total funds to be used for the share repurchase shall not be less than RMB250 million and not more than RMB500 million, and the price of the shares to be repurchased shall not be more than RMB52.00, inclusive, per share. The period of this share repurchase shall be 12 months from the date of the general meeting considering and approving the resolution regarding the share repurchase plan. The Company disclosed the Report on the Repurchase of Shares of the Company (《關於回購公司股份的報告書》) on December 7, 2018. On the same day, the Company implemented the share repurchase for the first time by centralized competitive bidding and disclosed the Announcement on the First Repurchase of Shares of the Company (《關於首次回購公司股份的公告》). On December 21, 2018, the Company disclosed the Announcement on the Repurchase of Shares of the Company Reaching 1% and the Progress in Repurchase (《關於回購公司股份比例達1%暨回購進展公告》). Please refer to the relevant announcements of the Company published on the website designated by CSRC for information disclosure (www.cninfo.com.cn) for details.
2. As of March 20, 2019, the implementation of the repurchase plan was completed. The Company repurchased 7,005,832 shares by centralized competitive bidding through the specific securities account for repurchase, accounting for 1.40% of the Company's total share capital. The highest transaction price was RMB49.50 per share and the lowest transaction price was RMB38.50 per share. The total transaction amount was RMB310,005,109.98 (inclusive of transaction fees). The Company disclosed the Announcement on the Repurchase of Shares of the Company Reaching 1% and the Progress in Repurchase (《關於回購公司股份比例達1%暨回購進展公告》) and the Report on the Progress in Repurchase of Shares of the Company (《關於回購公司股份的進展公告》) on December 21, 2018, January 2, 2019, February 1, 2019, and March 1, 2019, respectively. For details, please refer to the relevant announcements of the Company published on the website designated by CSRC for information disclosure (www.cninfo.com.cn). The implementation period of the Company's share repurchase was compliant with the requirements on repurchase plans (12 months from the date of the general meeting considering and approving the repurchase plan), and the actual number of shares repurchased, the repurchase price, and the total amount of funds used were in line with the repurchase plan reviewed and approved at the 2018 fourth extraordinary general meeting of the Company. No difference between the actual implementation and the original repurchase plan disclosed has been found. The Company has completed the repurchase in accordance with the repurchase plan disclosed.

Progress in implementation of the reduction of holdings of repurchased shares by centralized competitive bidding

Applicable Not applicable

IV. UNDERTAKINGS NOT YET PERFORMED BY THE COMPANY'S DE FACTO CONTROLLERS, SHAREHOLDERS, RELATED PARTIES, ACQUIRERS AND THE COMPANY DURING THE REPORTING PERIOD

✓ Applicable □ Not applicable

Source of undertaking	Undertaker	Type of undertaking	Content of undertaking	Time of undertaking	Duration of undertaking	Status of performance
Share incentive undertaking	Hangzhou Tigermed Consulting Co., Ltd.	Share incentive undertaking	The Company undertakes not to provide loans and any other forms of financial assistance to the incentive participants of the 2019 restricted shares for acquiring the relevant interests, including the provision of guarantee for their loans.	March 21, 2019	June 21, 2022	Normal
Undertaking made in acquisition report or report on changes in equity	Nil					
Undertaking made upon asset restructuring	Nil					
Undertaking made upon initial public offering or refinancing	Director, supervisor and senior management of the Company including Ye Xiaoping and Cao Xiaochun	Undertaking of trading moratorium	If I file my resignation within six months from the date of the initial public offering and listing of shares, I will not transfer the shares of the issuer directly or indirectly held within 18 months from the date of resignation. If I file my resignation from the 7th month to the 12th month after the date of initial public offering and listing of shares, I will not transfer the shares of the issuer directly or indirectly held within 12 months from the date of resignation. During the term of office as director, supervisor and senior management of the Company, the shares transferred by me each year shall not exceed 25% of the total number of shares of the issuer directly or indirectly held by me.	August 17, 2012	Long-term	Normal

Source of undertaking	Undertaker	Type of undertaking	Content of undertaking	Time of undertaking	Duration of undertaking	Status of performance
	Ye Xiaoping and Cao Xiaochun	Undertakings relating to peer competition, related party transactions and fund appropriation	I, other enterprises directly or indirectly controlled by me (other than the stock company) and the companies invested by me have not directly or indirectly engaged in any business or activity which competes or may compete with the business operated by the stock company.	August 17, 2012	Long-term	Normal
Undertaking made by others to minority shareholders of the Company	Nil					
Whether the undertaking is timely performed	Yes					
Where the undertaking is not performed during the Reporting Period, please explain the reason(s) for nonperformance and the following work plans	Nil					

V. COMPARISON TABLE ON USE OF RAISED FUNDS

Applicable Not applicable

VI. CAUTION AND EXPLANATION AS TO THE ANTICIPATED LOSS OF ACCUMULATED NET PROFIT FROM THE BEGINNING OF THE YEAR TO THE END OF THE NEXT REPORTING PERIOD OR SIGNIFICANT CHANGES OVER THE SAME PERIOD OF THE PREVIOUS YEAR

Applicable Not applicable

VII. ILLEGAL EXTERNAL GUARANTEES

Applicable Not applicable

During the Reporting Period, the Company did not have any illegal external guarantees.

VIII. INFORMATION ON NON-OPERATING USE OF FUNDS OF THE LISTED COMPANY BY CONTROLLING SHAREHOLDERS AND THEIR RELATED PARTIES

Applicable Not applicable

During the Reporting Period, the Company did not have any non-operating use of funds of the listed company by controlling shareholders and their related parties.

IX. REGISTRATION FORM FOR HOSTING FIELD TRIPS, COMMUNICATIONS AND INTERVIEWS DURING THE REPORTING PERIOD

Applicable Not applicable

During the Reporting Period, the Company did not host any field trips, communications and interviews.

SECTION 4 FINANCIAL STATEMENTS

I. FINANCIAL STATEMENTS

1. Consolidated balance sheet

Prepared by: Hangzhou Tigermed Consulting Co., Ltd.

	<i>Unit: RMB</i>	
Item	March 31, 2021	December 31, 2020
Current assets:		
Cash at bank and on hand	9,712,470,207.68	10,123,891,478.86
Settlement reserve		
Placements with banks and other financial institutions		
Financial assets held for trading	146,600,000.00	26,000,000.00
Derivative financial assets		
Note receivables	4,541,795.34	4,750,478.14
Accounts receivable	503,849,458.03	490,923,859.46
Accounts receivable financing		
Advances to suppliers	36,376,340.58	28,169,886.60
Premium receivables		
Amounts due from reinsurers		
Reinsurance contract reserve receivable		
Other receivables	114,859,709.79	113,925,261.11
Including: Interests receivable	19,493,014.02	11,866,249.46
Dividends receivable		
Financial assets purchased under agreements to resell		
Inventories	5,262,603.44	4,721,258.48
Contract assets	934,967,046.30	824,714,358.81
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets	38,447,698.46	28,873,044.92
Total current assets	11,497,374,859.62	11,645,969,626.38

Item	March 31, 2021	December 31, 2020
Non-current assets:		
Loans and advances to customers		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	58,067,134.33	60,269,574.65
Other equity instruments investment	14,659,848.00	15,157,777.32
Other non-current financial assets	6,229,583,443.63	5,292,301,027.14
Investment properties		
Fixed assets	317,343,811.70	300,362,837.51
Construction in progress	101,204,012.52	54,839,279.79
Bearer biological assets		
Oil and gas assets		
Right-of-use assets	324,851,952.39	327,466,541.14
Intangible assets	136,488,709.92	141,755,095.71
Development disbursements		
Goodwill	1,445,415,996.76	1,444,517,998.22
Long-term deferred expenses	32,037,780.03	33,428,024.51
Deferred tax assets	80,063,502.48	79,506,013.04
Other non-current assets	44,387,117.06	110,483,924.07
Total non-current assets	8,784,103,308.82	7,860,088,093.10
Total assets	20,281,478,168.44	19,506,057,719.48

Item	March 31, 2021	December 31, 2020
Current liabilities:		
Short-term borrowings		
Due to central banks		
Placements from banks and other financial institutions		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable		
Accounts payable	81,784,141.25	101,294,999.43
Advanced receipts		
Contract liabilities	622,772,456.70	484,643,033.92
Financial assets sold under agreement to repurchase		
Customer deposits and placements from other financial institutions		
Customer brokerage deposits		
Securities underwriting brokerage deposits		
Employee benefits payable	69,894,506.02	140,395,765.30
Tax payable	140,018,166.33	125,786,233.71
Other payables	158,273,818.95	181,298,257.12
Including: Interests payable		
Dividends payable	3,430,631.90	3,710,997.44
Fee and commissions payable		
Amounts due to reinsurer		
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	269,764,696.83	105,920,524.37
Other current liabilities		
Total current liabilities	1,342,507,786.08	1,139,338,813.85

Item	March 31, 2021	December 31, 2020
Non-current liabilities:		
Reserve of insurance contract		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual bond		
Lease liabilities	283,045,874.89	279,021,433.58
Long-term payables	22,282,565.53	97,493,781.83
Long-term employee benefits payable		
Provisions		
Deferred revenue		
Deferred tax liabilities	123,395,073.18	131,729,595.92
Other non-current liabilities		
Total non-current liabilities	428,723,513.60	508,244,811.33
Total liabilities	1,771,231,299.68	1,647,583,625.18
Owners' equity:		
Share capital	872,483,508.00	872,483,508.00
Other equity instruments		
Including: Preferred shares		
Perpetual shares		
Capital surplus	11,832,383,579.35	11,998,236,858.52
Less: Treasury stock	123,131,907.02	135,803,868.02
Other comprehensive income	-89,733,604.20	-92,013,282.09
Special reserve		
Surplus reserve	222,243,509.62	222,243,509.62
General risk provision		
Retained earnings	3,708,901,574.15	3,253,421,282.24
Total equity attributable to owners of the parent	16,423,146,659.90	16,118,568,008.27
Non-controlling interests	2,087,100,208.86	1,739,906,086.03
Total owners' equity	18,510,246,868.76	17,858,474,094.30
Total liabilities and owners' equity	20,281,478,168.44	19,506,057,719.48

Legal representative:
Cao Xiaochun

*Person-in-charge of
accounting:*
Gao Jun

*Head of accounting
department:*
Yu Guoyun

2. Balance sheet of the parent

Unit: RMB

Item	March 31, 2021	December 31, 2020
Current assets:		
Cash at bank and on hand	7,813,033,008.70	7,995,481,756.82
Financial assets held for trading		
Derivative financial assets		
Note receivables		
Accounts receivable	421,414,935.57	464,966,284.51
Accounts receivable financing		
Advances to suppliers	10,889,163.79	10,618,597.03
Other receivables	699,781,879.05	624,470,770.87
Including: Interests receivable	19,493,014.02	10,911,993.02
Dividends receivable	72,000,000.00	72,000,000.00
Inventories		
Contract assets	481,380,594.50	400,486,286.79
Assets classified as held-for-sale		
Non-current assets due within one year		
Other current assets		
Total current assets	9,426,499,581.61	9,496,023,696.02
Non-current assets:		
Bond investments		
Other bond investments		
Long-term receivables		
Long-term equity investments	4,933,047,065.16	4,352,814,224.99
Other equity instruments investment		
Other non-current financial assets	1,018,928,465.09	1,063,925,923.24
Investment properties		
Fixed assets	15,221,233.00	15,065,490.90
Construction in progress		
Bearer biological assets		
Oil and gas assets		
Right-of-use assets	49,197,727.12	46,845,572.26
Intangible assets	4,450,201.58	4,858,410.82
Development disbursements		
Goodwill		
Long-term deferred expenses	7,769,878.13	8,166,287.46
Deferred tax assets	13,651,297.47	14,806,845.80
Other non-current assets	4,408,741.23	106,296,252.57
Total non-current assets	6,046,674,608.78	5,612,779,008.04
Total assets	15,473,174,190.39	15,108,802,704.06

Item	March 31, 2021	December 31, 2020
Current liabilities:		
Short-term borrowings		
Financial liabilities held for trading		
Derivative financial liabilities		
Notes payable		
Accounts payable	532,175,290.75	470,669,120.03
Advanced receipts		
Contract liabilities	224,160,155.81	113,872,404.85
Employee benefits payable	10,358,850.31	29,522,208.26
Tax payable	72,620,223.88	46,368,955.40
Other payables	474,969,241.51	490,289,268.44
Including: Interests payable		
Dividends payable	1,698,469.34	1,698,469.34
Liabilities classified as held-for-sale		
Non-current liabilities due within one year	191,432,032.99	42,900,642.71
Other current liabilities		
Total current liabilities	1,505,715,795.25	1,193,622,599.69
Non-current liabilities:		
Long-term borrowings		
Bonds payable		
Including: Preferred shares		
Perpetual shares		
Lease liabilities	40,654,126.54	35,709,634.80
Long-term payables		49,612,500.00
Long-term employee benefits payable		
Provisions		
Deferred revenue		
Deferred tax liabilities	75,269,845.57	82,019,464.30
Other non-current liabilities		
Total non-current liabilities	115,923,972.11	167,341,599.10
Total liabilities	1,621,639,767.36	1,360,964,198.79
Owners' equity:		
Share capital	872,483,508.00	872,483,508.00
Other equity instruments		
Including: Preferred shares		
Perpetual shares		
Capital surplus	11,516,805,293.20	11,506,248,761.99
Less: Treasury stock	123,131,907.02	135,803,868.02
Other comprehensive income		
Special reserve		
Surplus reserve	221,923,225.86	221,923,225.86
Retained earnings	1,363,454,302.99	1,282,986,877.44
Total owners' equity	13,851,534,423.03	13,747,838,505.27
Total liabilities and owners' equity	15,473,174,190.39	15,108,802,704.06

3. Consolidated income statement

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Total revenue	901,947,880.46	650,105,123.66
Including: Operating income	901,947,880.46	650,105,123.66
Interest income		
Premium earned		
Fees and commission income		
II. Total cost of sales	613,105,133.93	495,950,303.74
Including: Operating cost	478,741,538.49	349,487,695.09
Interest expenses		
Fees and commission expenses		
Cash surrender value		
Claim settlement expenses, net		
Net provision for insurance contracts		
Policy dividend expense		
Reinsurance expenses		
Business tax and surcharge	3,854,298.60	2,248,849.29
Selling expenses	31,636,114.04	22,956,268.92
General and administrative expenses	114,168,850.78	80,270,262.77
Research and development expenses	46,970,780.14	38,356,015.86
Finance expenses	-62,266,448.12	2,631,211.81
Including: Interest expense		
Interest income		
Add: Other income	2,611,291.27	2,124,250.86
Investment income		
(losses are expressed by “-”)	32,367,209.75	76,632,752.61
Including: Income from investment in associates and joint ventures		
Gain on derecognition of financial assets at amortized cost		
Foreign exchange gain		
(losses are expressed by “-”)		
Net exposure hedging gain		
(losses are expressed by “-”)		
Gain from fair value change		
(losses are expressed by “-”)	438,176,790.03	57,707,345.36
Credit impairment loss		
(losses are expressed by “-”)	-210,159.45	-4,159,621.69
Asset impairment loss		
(losses are expressed by “-”)	-5,485,486.02	
Gain on disposal of assets		
(losses are expressed by “-”)	-5,029.98	-14,582.95

Item	Amount for the period	Amount for the prior period
III. Operating profit (losses are expressed by “-”)	756,297,362.13	286,444,964.11
Add: Non -operating income	917,616.80	1,764,347.24
Less: Non -operating expenses	50,955.93	2,950,955.38
IV. Profit before tax (total losses are expressed by “-”)	757,164,023.00	285,258,355.97
Less: Income tax expenses	34,609,998.43	25,925,635.58
V. Net profits (net losses are expressed by “-”)	722,554,024.57	259,332,720.39
(A) By continuing operation		
1. Net profit from continuing operations (net losses are expressed by “-”)	722,554,024.57	259,332,720.39
2. Net profit from discontinued operations (net losses are expressed by “-”)		
(B) By ownership of equity		
1. Net profit attributable to owners of the parent	455,480,291.91	254,960,034.72
2. Non-controlling interests	267,073,732.66	4,372,685.67
VI. Other comprehensive income, net of tax	3,549,978.18	24,666,511.86
Other comprehensive income attributable to owners of the parent, net of tax	2,279,677.89	13,356,674.66
(A) Items that will not be reclassified subsequently to profit or loss		
1. Remeasurements gains/(losses) of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss		
3. Change in fair value of other equity instruments investment		
4. Change in fair value of credit risk of the Company		
5. Others		

Item	Amount for the period	Amount for the prior period
(B) Items that may be reclassified to profit or loss	2,279,677.89	13,356,674.66
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investment		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investment		
5. Cash flow hedge reserve		
6. Currency translation difference	2,279,677.89	13,356,674.66
7. Others		
Other comprehensive income attributable to non-controlling interests, net of tax	1,270,300.29	11,309,837.20
VII. Total comprehensive income	726,104,002.75	283,999,232.25
Total comprehensive income attributable to owners of the parent	457,759,969.80	268,316,709.38
Total comprehensive income attributable to non-controlling interests	268,344,032.95	15,682,522.87
VIII. Earnings per share:		
(A) Basic earnings per share	0.52	0.34
(B) Diluted earnings per share	0.52	0.34

<i>Legal representative:</i> Cao Xiaochun	<i>Person-in-charge of accounting:</i> Gao Jun	<i>Head of accounting department:</i> Yu Guoyun
---	--	---

4. Income statement of the parent

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Operating income	369,893,469.81	269,555,678.50
Less: Operating cost	242,380,367.74	186,804,292.68
Business tax and surcharge	1,602,984.68	553,524.12
Selling expenses	9,319,812.45	6,754,871.86
General and administrative expenses	30,327,517.55	20,962,099.72
Research and development expenses	16,996,836.41	12,147,552.26
Finance expenses	-63,061,957.66	5,760,775.56
Including: Interest expense		
Interest income		
Add: Other income	1,123,417.42	1,041,663.19
Investment income (losses are expressed by “-”)	-538,287.48	5,059,625.48
Including: Income from investment in associates and joint ventures		
Gain on derecognition of financial assets at amortized cost		
Net exposure hedging gain (losses are expressed by “-”)		
Gain from fair value change (losses are expressed by “-”)	-52,997,458.15	14,592,822.07
Credit impairment loss (losses are expressed by “-”)	16,560,460.22	-9,411,806.04
Asset impairment loss (losses are expressed by “-”)	-4,939,690.80	
Gain on disposal of assets (losses are expressed by “-”)		-10,516.80
II. Operating profit (losses are expressed by “-”)	91,536,349.85	47,844,350.20
Add: Non -operating income	70,700.00	0.15
Less: Non -operating expenses	1,074.59	1,105,429.31
III. Profit before tax (total losses are expressed by “-”)	91,605,975.26	46,738,921.04
Less: Income tax expenses	11,138,549.71	6,563,788.24

Item	Amount for the period	Amount for the prior period
IV. Net profits (net losses are expressed by “-”)	80,467,425.55	40,175,132.80
(A) Net profit from continuing operations (net losses are expressed by “-”)	80,467,425.55	40,175,132.80
(B) Net profit from discontinued operations (net losses are expressed by “-”)		
V. Other comprehensive income, net of tax		
(A) Items that will not be reclassified subsequently to profit or loss		
1. Remeasurements gains/(losses) of defined benefit obligation		
2. Other comprehensive income accounted for using the equity method, which will not be reclassified subsequently to profit or loss		
3. Change in fair value of other equity instruments investment		
4. Change in fair value of credit risk of the Company		
5. Others		
(B) Items that may be reclassified to profit or loss		
1. Other comprehensive income accounted for using the equity method, which may be reclassified subsequently to profit or loss		
2. Change in fair value of other bond investment		
3. Other comprehensive income due to reclassification of financial assets		
4. Credit impairment loss on other bond investment		
5. Cash flow hedge reserve		
6. Currency translation difference		
7. Others		
VI. Total comprehensive income	80,467,425.55	40,175,132.80
VII. Earnings per share:		
(A) Basic earnings per share	0.09	0.05
(B) Diluted earnings per share	0.09	0.05

5. Consolidated cash flow statement

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	970,767,440.21	631,849,246.48
Net increase in customer deposits and placements from other banks		
Net increase in due to central bank		
Net increase in borrowings from other financial institutions		
Cash from premiums on original insurance contracts		
Cash received from reinsurance business, net		
Net increase in insured's deposits and investments		
Cash received from interests, fees and commissions		
Net increase in placements from banks and other financial institutions		
Net increase of funds in repurchase business		
Net cash received from customer brokerage		
Tax refunds		
Cash receipts related to other operating activities	68,202,744.45	53,997,827.27
Sub-total of cash inflows from operating activities	1,038,970,184.66	685,847,073.75
Cash paid for goods and services	238,593,268.97	189,049,195.24
Net increase in loans and advances to customers		
Net increase in deposits with central bank and other banks		
Cash paid for claim settlements on original insurance contracts		
Net increase in placements with banks and other financial institutions		
Cash paid for interest, fees and commissions		
Cash paid for policy dividends		
Cash paid to employees and for employee benefits	432,339,078.57	310,588,342.54
Payments of all types of taxes	65,816,603.50	59,148,893.69
Cash payments related to other operating activities	63,881,475.79	38,144,584.30
Sub-total of cash outflows from operating activities	800,630,426.83	596,931,015.77
Net cash flows from operating activities	238,339,757.83	88,916,057.98

Item	Amount for the period	Amount for the prior period
II. Cash flows from investing activities:		
Cash received from sale of investments	233,430,888.66	118,316,491.12
Cash receipts from returns on investments	1,783,275.33	24,178,048.67
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	688.68	
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities		
Sub-total cash inflows from investing activities	235,214,852.67	142,494,539.79
Cash paid to acquire fixed assets, intangible assets and other long-term assets	131,739,205.66	35,608,736.69
Cash paid for investments	850,152,025.64	317,774,550.92
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business units		94,909,462.10
Cash payments related to other investing activities		
Sub-total of cash outflows from investing activities	981,891,231.30	448,292,749.71
Net cash flows from investing activities	-746,676,378.63	-305,798,209.92
III. Cash flows from financing activities:		
Cash receipts from capital contributions	89,949,826.80	25,972,869.32
Including: Cash receipts from capital contributions from non-controlling interests of subsidiaries		
Cash received from borrowings		357,200,000.00
Cash receipts related to other financing activities	12,671,961.00	
Sub-total of cash inflows from financing activities	102,621,787.80	383,172,869.32
Cash repayments for debts		142,965,505.01
Cash payments for distribution of dividends, profit or interest expenses	4,145,335.43	13,865,589.30
Including: Profit and dividends paid to non-controlling interests by the subsidiaries		
Cash payments related to other financing activities	15,515,279.26	9,069,454.77
Sub-total of cash outflows from financing activities	19,660,614.69	165,900,549.08
Net cash flows from financing activities	82,961,173.11	217,272,320.24
IV. Effects of foreign exchange rates changes on cash and cash equivalents		
	19,316,437.04	19,439,642.18
V. Net increase in cash and cash equivalents		
Add: Cash and cash equivalents at beginning of the period	-406,059,010.65	19,829,810.48
	9,959,963,262.81	2,037,086,066.70
VI. Cash and cash equivalents at end of the period		
	9,553,904,252.16	2,056,915,877.18

6. Cash flow statement of the parent

Unit: RMB

Item	Amount for the period	Amount for the prior period
I. Cash flows from operating activities:		
Cash received from sale of goods or rendering of services	407,033,274.53	213,775,608.76
Tax refunds		
Cash receipts related to other operating activities	113,037,251.87	69,609,422.81
Sub-total of cash inflows from operating activities	520,070,526.40	283,385,031.57
Cash paid for goods and services	129,943,609.94	51,799,928.77
Cash paid to employees and for employee benefits	106,430,040.31	87,852,731.95
Payments of all types of taxes	5,935,725.93	11,604,957.93
Cash payments related to other operating activities	96,647,536.75	64,701,033.87
Sub-total of cash outflows from operating activities	338,956,912.93	215,958,652.52
Net cash flows from operating activities	181,113,613.47	67,426,379.05
II. Cash flows from investing activities:		
Cash received from sale of investments	9,300,000.00	
Cash receipts from returns on investments		2,000,000.00
Net cash received from disposal of fixed assets, intangible assets and other long-term assets		
Net cash received from disposal of subsidiaries and other business units		
Cash receipts related to other investing activities		
Sub-total cash inflows from investing activities	9,300,000.00	2,000,000.00
Cash paid to acquire fixed assets, intangible assets and other long-term assets	2,847,929.88	132,020.00
Cash paid for investments	376,634,548.32	100,000,000.00
Net cash paid for acquisition of subsidiaries and other business units		165,145,383.01
Cash payments related to other investing activities		
Sub-total of cash outflows from investing activities	379,482,478.20	265,277,403.01
Net cash flows from investing activities	-370,182,478.20	-263,277,403.01
III. Cash flows from financing activities:		
Cash receipts from capital contributions		
Cash received from borrowings		357,200,000.00
Cash receipts related to other financing activities	12,671,961.00	
Sub-total of cash inflows from financing activities	12,671,961.00	357,200,000.00
Cash repayments for debts		141,800,000.00
Cash payments for distribution of dividends, profit or interest expenses		7,117,622.87
Cash payments related to other financing activities	4,193,383.24	
Sub-total of cash outflows from financing activities	4,193,383.24	148,917,622.87
Net cash flows from financing activities	8,478,577.76	208,282,377.13

Item	Amount for the period	Amount for the prior period
IV. Effects of foreign exchange rates changes on cash and cash equivalents	-1,858,461.15	275,054.18
V. Net increase in cash and cash equivalents	-182,448,748.12	12,706,407.35
Add: Cash and cash equivalents at beginning of the period	7,995,481,756.82	126,988,177.98
VI. Cash and cash equivalents at end of the period	7,813,033,008.70	139,694,585.33

II. EXPLANATION OF FINANCIAL STATEMENTS ADJUSTMENT

1. Adjustment to relevant items in the financial statements at the beginning of the year due to implementation of the New Lease Standard for the first time in 2021

Applicable Not applicable

2. Explanation of retrospective adjustments to comparative information for prior period due to initial implementation of the New Lease Standard since 2021

Applicable Not applicable

III. AUDIT REPORT

Whether the first quarterly report is audited

Yes No

The first quarterly report of the Company is unaudited.

This report was originally prepared in Chinese. In the event of discrepancies between the Chinese and English version, the Chinese version shall prevail.